KalVista Pharmaceuticals (KALV) Total Liabilities (2014 - 2025)

KalVista Pharmaceuticals (KALV) has 12 years of Total Liabilities data on file, last reported at $215.5 million in Q3 2025.

• For the quarter ending Q3 2025, Total Liabilities rose 7.65% year-over-year to $215.5 million; the trailing twelve-month figure through Jul 2025 stood at $215.5 million (up 7.65% YoY), and the FY2025 full-year result was $250.8 million, up 6.53% from the prior year.
• Total Liabilities retreated to $215.5 million in Q3 2025, from $250.8 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $272.0 million in Q2 2021 to a low of $66.2 million in Q1 2021.
• A 5-year average of $189.9 million and a median of $200.2 million in 2024 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities soared 239.93% in 2022 and slumped 43.99% in 2024, its largest moves.
• Tracing KALV's Total Liabilities over 5 years: stood at $243.8 million in 2021, then slumped by 33.21% to $162.8 million in 2022, then dropped by 14.8% to $138.7 million in 2023, then retreated by 5.97% to $130.5 million in 2024, then surged by 65.19% to $215.5 million in 2025.
• Business Quant data shows KALV's Total Liabilities at $215.5 million in Q3 2025, $250.8 million in Q2 2025, and $130.5 million in Q4 2024.